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Background: Human genetic research has implicated functional
variants of more than one hundred genes in the modulation of
persisting pain. Artificial intelligence and machine-learning techniques
may combine this knowledge with results of genetic research gathered
in any context, which permits the identification of the key biological
processes involved in chronic sensitization to pain.
Methods: Based on published evidence, a set of 110 genes carrying
variants reported to be associated with modulation of the clinical
phenotype of persisting pain in eight different clinical settings was
submitted to unsupervised machine-learning aimed at functional
clustering. Subsequently, a mathematically supported subset of genes,
comprising those most consistently involved in persisting pain, was
analysed by means of computational functional genomics in the Gene
Ontology knowledgebase.
Results: Clustering of genes with evidence for a modulation of
persisting pain elucidated a functionally heterogeneous set. The situation
cleared when the focus was narrowed to a genetic modulation
consistently observed throughout several clinical settings. On this basis,
two groups of biological processes, the immune system and nitric oxide
signalling, emerged as major players in sensitization to persisting pain,
which is biologically highly plausible and in agreement with other lines
of pain research.
Conclusions: The present computational functional genomics-based
approach provided a computational systems-biology perspective on
chronic sensitization to pain. Human genetic control of persisting pain
points to the immune system as a source of potential future targets for
drugs directed against persisting pain. Contemporary machine-learned
methods provide innovative approaches to knowledge discovery from
previous evidence.
Significance: We show that knowledge discovery in genetic databases
and contemporary machine-learned techniques can identify relevant
biological processes involved in Persitent pain.
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1. Introduction
Persisting pain has a high prevalence (Elliott et al.,
1999; Breivik et al., 2006; van Hecke et al., 2013)
affecting a significant proportion of the world’s pop-
ulation (Breivik et al., 2006). Its pathophysiology is
incompletely understood, which is reflected in the
limited success of available treatment options (Moore
et al., 2009, 2012; Derry et al., 2012) and has stimu-
lated intense research on this topic (Kringel and
L€otsch, 2015). In this context, the study of human
gene polymorphisms that modulate the persisting
pain phenotype is an accepted research approach
which has been pursued for more than 50 years
(Godinova, 1965). A genetic background to persist-
ing pain is clearly reflected by a protective effect
against persisting pain exerted, for example, by a
haplotype of the guanosine-50-triphosphate (GTP)
cyclohydrolase 1 gene (GCH1), originally reported to
be composed of 15 genetic variants (Tegeder et al.,
2006, 2008), or by a reduction in the perceived
intensity of pain exerted, for example, by a deletion/
insertion variant in the serotonin transporter gene-
linked polymorphic region (5-HTTLPR; gene:
SLC6A4) reportedly reducing the perception of heat
pain (Lindstedt et al., 2011; Hooten et al., 2013;
Kunz et al., 2016). On the other hand, increased risk
for persisting pain is conferred, for example, by the
rs12584920 variant of the 5-hydroxytryptamine
receptor 2A gene (HTR2A) (Nicholl et al., 2011) or
the rs734784 polymorphism in the potassium volt-
age-gated channel modifier, subfamily S member 1,
gene (KCNS1) (Costigan et al., 2010).
Human genetic research during the last decade has
identified many common variants of more than a
hundred different genes spread across the genome
that modulate the phenotype of persisting pain in sev-
eral different clinical settings (Table 1). Thanks to
concomitant developments in computer science,
including progress in artificial intelligence, machine-
learning and knowledge discovery in databases (Ash-
burner et al., 2000), the analysis of fundamental,
complex biological functions has become increasingly
possible. This allows persisting pain to be approached
at a functional genomics level by combining the infor-
mation on genetic modulation acquired in clinical
studies with current knowledge of the function of
human genes. This active research topic has already
led to the identification of candidate genes for further
clinical genetic pain research (L€otsch et al., 2013) and
highlighted key pathophysiological processes of pain
which may be targeted for future pharmacological
treatment options (Ultsch et al., 2016).
In the present analysis, information on genes,
for which empirical evidence indicates the exis-
tence of variants that modulate the clinical pheno-
type of persisting pain, was analysed at a
functional genomics level. In this way, the bio-
chemical, cellular and/or physiological properties of
each and every gene product can be investigated
to gain an understanding of the relationship
between the genome and the phenotype on a glo-
bal genomewide scale (Gibson and Muse, 2009).
Applying machine-learned techniques (Fig. 1), the
genes currently known to have relevance to
human persisting pain were analysed for functional
patterns that may provide insight into its patho-
physiology based on current research activities,
applying a data-driven approach without using
prior hypotheses about the most important biologi-
cal functions characterizing persisting pain. By
applying methods of precisely calculated item selec-
tion (Ultsch and L€otsch, 2015), the present analysis
aimed to identify a subset of genes that were most
consistently reported to be involved in the modula-
tion of persisting pain with a subsequent analysis
of the main biological functions exerted by the
products of these genes.
2. Methods
2.1 Search strategy
A set of genes relevant to persisting pain, based on
published associations of their variants with pheno-
typic differences in persisting pain patients, was
obtained from (1) a PubMed database (accessed in
August 2016), by searches for the string ‘(chronic
OR persisting OR neuropathic OR back OR inflam-
matory OR musculoskeletal OR visceral OR wide-
spread OR idiopathic OR fibromyalgia) AND pain
AND (polymorphism OR variant) NOT review’ and
(2) publications starting from the year 2000, which
is close to the first sequencing of the human genome
(Lander et al., 2001; Venter et al., 2001) marking
the beginning of a new area of genetic research, and
(3) published overviews on pain genetics (e.g.
Edwards, 2006; Tegeder and L€otsch, 2009; Mogil,
2012; Zorina-Lichtenwalter et al., 2016). To avoid
redundancies, reports of positive associations of any
gene variant were included only once per clinical
setting in the present analysis. This implies that not
every variant found to be functionally associated
with a persisting pain phenotype was taken into
account. The resulting information for each gene,
thus, comprised (1) a positive report of a gene
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modulation in persisting pain and (2) the clinical set-
ting of this finding.
2.2 Data analysis
Data were analysed using the R software package
(version 3.3.2 for Linux; http://CRAN.R-project.org/;
R Development Core Team, 2008) on an Intel Xeon
computer running on Ubuntu Linux 16.04.1 64-bit.
The analysis employed several methods of machine-
learning that, as described previously (L€otsch and
Ultsch, 2017a), may be referred to as a set of meth-
ods that can automatically detect patterns in data
and then use the uncovered patterns to predict or
classify future data, to observe structures such as
subgroups in the data or to extract information from
the data suitable to derive new knowledge (Murphy,
2012; Dhar, 2013). More detailed descriptions
including definitions of key concepts have been pro-
vided elsewhere (L€otsch and Ultsch, 2017a).
The analysis aimed at describing the functional
genomics of persisting pain based on the biological
roles of the genes that reportedly carry variants
modulating that phenotype. The biological roles
were assessed as biological processes in which the
genes are involved, defined as series of events or
molecular functions with a defined beginning and
end (Ashburner et al., 2000) and queried from the
Gene Ontology (GO) knowledgebase that provides
the acquired knowledge about the biological func-
tions of gene products, described with a controlled
vocabulary of GO terms (Ashburner et al., 2000).
Thus, the basis on which the present functional
picture of persisting pain was created consisted of
the biological processes in which the genes carrying
modulatory variants were reported to be involved.
The functional picture of persisting pain was sought
pursuing two different analytical paths (Fig. 1). In a
first approach, functional subgroups were sought in
the set of human genes, variants of which have
been associated with modulation of the clinical phe-
notype of persisting pain. This was addressed by
applying a clustering algorithm on the matrix given
by the genes versus their annotated biological pro-
cesses; an approach that previously proofed as suit-
able for gene function based classifications (L€otsch
and Ultsch, 2016a). In a second approach, the
hypothesis was pursued that the functional geno-
mics of persisting pain will prevail across clinical
settings irrespective of the disease that had origi-
nally triggered the process. Therefore, the most
informative subsets of the genes were identified
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(Ultsch and L€otsch, 2015) and subsequently, tech-
niques of knowledge discovery were applied to
identify the particular biological roles exerted by
this set of genes as opposed to the biological func-
tions exerted by a similarly sized random set of
genes. This analysis was performed twice, once
using the most informative genes resulting from
above-mentioned analysis, and, to strengthen the
evidence for pain reliance, again using the addi-
tional selection criterion that the genes should be
listed among pain-relevant genes in the PainGenes
database (Lacroix-Fralish et al., 2007). The analyti-
cal steps are described in detail in the following.
2.2.1 Functional clustering of genes
A first analytical approach to the functional geno-
mics of persisting pain reflected in the set of genes
that carry variants reported to modulate the pheno-
type aimed at finding functional clusters of genes.
2.2.2 Generation of a gene versus functional
feature matrix
As a prerequisite for functional clustering of genes, a
gene versus function matrix was created. Therefore,
the biological functions in which the genes, or their
products, are involved were queried from the GO
knowledge base (http://www.geneontology.org/). The
GO knowledge base is searchable for three major cate-
gories, consisting of biological process, cellular compo-
nent and molecular function. As the most suitable
representation of processes that are involved in the
chronification of central sensitization to pain, the GO
category biological process was selected as previously
(L€otsch et al., 2013; L€otsch and Ultsch, 2016b; Ultsch
et al., 2016). According to the GO knowledgebase, this
category contains one or more ordered collections of
molecular functions involving chemical or physical
transformations such as cell growth and maintenance
or signal transduction (Ashburner et al., 2000).
Figure 1 Flow chart of the data analysis. The figure provides an overview of the machine-learning and data science approach applied, specifying
the data flow of the gene sets and the analyses applied to them. The figure follows the analytical flow (left column of blue rectangles, separated
by horizontal dashed lines) that following data collection from the literature was implemented as two analytical approaches comprising (1) func-
tional gene clustering and (2) a computational functional genomics analysis of the biological roles of the genes implicated in the modulation of per-
sisting pain in various clinical settings. The coloured frames show the presented analysis, the grey frames the intermediate data flows.
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However, not all processes known to be influenced
by the genes were sought, but only those that were
annotated to the present set of genes more often
than expected for any similarly sized random set of
genes. Therefore, to capture biological processes that
are particularly relevant to the present gene set, the
set of genes was submitted to overrepresentation
analysis (ORA; Backes et al., 2007). As intended, this
compared the occurrence (as defined by its annota-
tion term) of the particular set of genes covered by a
GO term with the number of genes expected to be
defined by this term. The significance of the associa-
tion of a GO term with the expected list of genes
was determined by means of a Fisher’s exact test
(Fisher, 1922). A p-value threshold, tp, of 1 9 10
6
was applied and subsequently, the obtained results
were additionally corrected for multiple testing
according to Bonferroni (Hochberg, 1988). The result
was the desired ‘gene versus biological process’
matrix (Fig. 2) that, rescaled as [0,1] indicating the
absence or presence, respectively, of the involvement
of a gene in a particular biological process, provided
a filtered representation of the particularly important
processes in which the analysed genes were involved
while disregarding processes that would have been
found by chance in any similarly sized gene set. This
ORA-based filtering of gene functions was previously
found to facilitate the functional analysis of gene sets
including a context of pain and analgesia (L€otsch
and Ultsch, 2016a; L€otsch et al., 2017).
2.2.3 Machine-learned cluster detection
Following the creation of the gene versus functional
feature matrix, expressed as ‘gene versus biological
process’ matrix, the feature space required for func-
tional gene clustering was established as D ¼ fðxiÞ j
xi 2 Nd; i ¼ 1; . . .; ng comprising the d biological pro-
cess to which the n genes in the analysed set were
annotated. This feature space was searched for a clus-
ter structure. Among several methods available for
clustering, a method of unsupervised machine-learn-
ing shown recently to provide a viable unbiased clus-
tering of high-dimensional biomedical data,
outperforming classical clustering algorithms (Ultsch
and L€otsch, 2017), was chosen. Specifically, the data
space was projected from the high-dimensional fea-
ture space D onto a two-dimensional self-organizing
map (SOM) of the Kohonen type (Kohonen, 1982).
This map was composed of a toroid grid (Ultsch,
2003), i.e. a projection plane where opposite edges are
connected. The grid had a size of 25 9 35 artificial
neurons chosen according to the proposals of SOM
size determination described previously (Ultsch and
L€otsch, 2017). Each of the artificial neurons held a
position vector, which carried the information about
the biological processes associated with each gene,
and a further parameter, which carried ‘weights’ of
the same dimensions as the input dimensions. The
weights were initially randomly drawn from the range
of the data variables and subsequently adapted to the
data during the learning phase of 25 epochs. The
Euclidean distance was used for process (dis-)similar-
ity; very general processes, such as ‘biological process’
that is the root term of the polyhierarchy carry the
same value for all genes and therefore do not influ-
ence this distance. Following training of the neural
network, an emergent SOM (ESOM; L€otsch and
Ultsch, 2014; Ultsch and Sieman, 1990) was obtained
that represented the genes as the localizations of their
‘best matching units’ (BMU), which are neurons that
carried the vector most similar to a gene’s data vector.
Following the projection of the data on the grid of
neurons, an extension of the Kohonen map was
applied to obtain clusters of genes. Specifically, the
distance structure in the high-dimensional space was
visualized using the so-called U-matrix (Ultsch and
Sieman, 1990; L€otsch and Ultsch, 2014). The clusters
became visible using a geographical map analogy
where ‘mountain ranges’ represent large distances in
the feature space that can be used to visually sepa-
rate data clusters, whereas low ‘valleys’ represent
sets of genes that are related to similar biological
processes and therefore belong to the same cluster.
The ‘map’ was further enhanced by calculating a
so-called P-matrix (Ultsch, 2003), which displays the
probability of a data point as pðxÞ ¼j fdata points xi j
dðxi; xÞ\ ¼ rg j estimated as the number of data
points in a sphere with radius r around x at each
grid point on the ESOM’s output grid. The calcula-
tions were performed using our R library ‘Umatrix’
(https://cran.r-project.org/package=Umatrix; L€otsch
et al., 2018a).
2.2.4 Functional genomics analysis of most
informative genes reported to modulate persisting
pain
A second analytical approach at the functional geno-
mics of persisting pain reflected in the set of genes
that carry variants reported to modulate the pheno-
type aimed at identifying the biological roles of those
genes that had been implicated most consistently in
this context. Specifically, the present analysis aimed
at the discovery of new knowledge about pain,
rather than about the underlying disease, from
© 2018 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of Eur J Pain 22 (2018) 1735--1756 1741
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reports about a genetic modulation of a clinical
symptom involving pain. This implies a distinction
between the modulation of pain and the modulation
of the disease-causing pain that has usually not been
made in the included reports. For example, in rheu-
matic diseases a genetic variant could modulate the
progress and severity of inflammatory processes and
via this it could finally modulate pain, or a genetic
variant could directly modulate the individual per-
ception of pain and therefore, similar nociceptive
stimuli produced by the inflammatory processes
could cause different degrees of pain. However, in
the interest of the present analysis, we assessed only
the direct modulations of pain, which were expected
to be provided most likely by those genes that had
been implicated in modulation of persisting pain in
more than one clinical setting.
2.2.5 Identification of genes most consistently
reported to modulate persisting pain
To identify the most informative subset of genes
reportedly modulating clinical persisting pain, a
cut-off criterion had to be defined for the number
of different clinical settings required for inclusion
in further analyses. To avoid arbitrary criteria, the
cut-off was obtained by applying an item catego-
rization technique used to separate ‘the important
few’ from the ‘trivial many’ (Juran, 1975). As a
most suitable technique, because providing a math-
ematically based cut-off, computed ABC analysis
was chosen for the present purpose, supported by
previous demonstrations that it is suitable for item
selection tasks in biomedical research (Ultsch and
L€otsch, 2015; L€otsch and Ultsch, 2017b; L€otsch
et al., 2018b).
ABC analysis requires a set of positive numbers,
which was given by the column sums of the ‘clini-
cal settings versus genes’ matrix (Fig. 4 top). The
vector of the sums of clinical settings with positive
reports of the modulatory involvement a gene’s
variant was submitted to computed ABC analysis
(Ultsch and L€otsch, 2015), which aims to divide a
set of positive data – here the set of genes scored
according to their involvement in clinical settings
Figure 2 Matrix plot of the association of identified genes (rows; Table 1) with biological processes (columns), according to the annotations of
the Gene Ontology (GO) knowledgebase (Ashburner et al., 2000), filtered for statistical significance in the present context by means of an overrep-
resentation analysis with a p-value threshold of 1 9 106 and correction for multiple testing according to Bonferroni. The matrix displays a yes/no
scaling [1,0], colour-coded as blue or white, respectively. The figure has been created using the R software package (version 3.3.2 for Linux; http://
CRAN.R-project.org/; R Development Core Team, 2008). Specifically, this plot was created using the ‘heatmap.2’ functions of the R package ‘gplots’
(Warnes G. R.; https://cran.r-project.org/package=gplots) with the build-in clustering of the plotting routine disabled (R switches ‘Colv = FALSE,
Rowv = FALSE’). For descriptions of the GO terms (abscissa), see the AmiGO search tool at http://amigo.geneontology.org/ (Carbon et al., 2009).
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of persisting pain - into three disjointed subsets
called ‘A’, ‘B’ and ‘C’. Subset ‘A’ comprises ‘the
important few’, subset ‘C’ comprises clearly non-
profitable values, i.e. ‘the trivial many’ (Juran,
1975), whereas subset ‘B’ includes items that pro-
vide still a balance between effort and gain. There-
fore, the limit separating subset ‘C’, i.e. the genes
for which a modulation of persisting clinical pain
provides the least relevant information, was chosen
as the limit for the inclusion of genes in further
analyses. These calculations were made using our
R package ‘ABCanalysis’ (https://cran.r-project.org/
package=ABCanalysis; Ultsch and L€otsch, 2015).
2.2.6 Functional genomics analysis of genes most
consistently reported to modulate persisting pain
Following identification of the most informative
genes as members of ABC sets ‘A’ or ‘B’, the func-
tional genomics picture of persisting pain arising
from these genes was analysed. This was obtained
by applying ORA as described above, again using a
p-value threshold of tp = 1 9 10
6 with Bonferroni
a-correction for multiple testing. The focus of this
analysis was, however, the hierarchical representa-
tion of the complete knowledge on the biological
roles of genes that carry polymorphisms observed
to modulate persisting pain phenotypes. This was
provided in a directed acyclic graph (DAG; Thu-
lasiraman and Swamy, 1992). In this graph, the
top-down, branching polyhierarchy of GO terms
starts with the most broadly defined terms and
progresses towards the branches, representing GO
terms with the narrowest definition (details). These
calculations were made using our R package
‘dbtORA’ (https://github.com/IME-TMP-FFM/db
tORA; Lippmann et al., 2018), which has been
designed for knowledge discovery in the GO.
As the complete DAG usually contains many GO
terms (e.g. 64 GO terms in the present ORA), the
information was transformed into a more intelligible
form using the method of ‘functional abstraction’
(Ultsch and L€otsch, 2014). This aims to reduce the
numbers of GO terms using a heuristic search algo-
rithm that identifies so-called functional areas
(Ultsch and L€otsch, 2014), which are GO terms that
qualify by their informational importance as headli-
nes representing specific aspects (taxonomies) of the
complete DAG with maximal coverage, precision,
informational value and conciseness (Ultsch and
L€otsch, 2014).
To narrow the focus even more to pain-relevant
genes, the ORA was repeated using the set
intersection of the most informative genes identified
as described above by means of ABC analysis, with
the genes listed among known pain-relevant genes
in the PainGenes database (http://www.jbldesign.
com/jmogil/enter.html; Lacroix-Fralish et al., 2007).
These mainly include genes found, in at least three
independent studies in transgenic mice, to contribute
to the modulation of pain and identified using
PubMed searches, with the addition of further genes
(L€otsch et al., 2013) comprising those causally impli-
cated in human hereditary diseases associated with
extreme pain phenotypes (summarized in, e.g.
L€otsch et al., 2017), and genes coding for the targets
of approved analgesic drugs or of novel analgesics
currently in clinical phases of development (L€otsch
and Geisslinger, 2011). This provided a set of
n = 535 ‘pain genes’ (Fig. 1 bottom).
3. Results
As a result of a literature search, a total of 110
unique genes were identified in eight different
clinical settings of chronic central sensitization to
pain, including back pain, inflammatory pain, mus-
culoskeletal pain, neuropathic pain, visceral pain,
widespread pain, idiopathic pain and miscellaneous
pain, for which functional associations of genetic
variants with differences in the phenotype of per-
sisting pain had been reported (Table 1). Some of
the included studies used a genomewide approach;
however, many were candidate gene studies.
3.1 Functional clustering of genes carrying
variants reportedly modulating persisting
clinical pain
In a first analytical approach, functional subgroups
were sought in the set of human genes, variants of
which have been associated with modulation of the
clinical phenotype of persisting pain. A filtered
representation of the particularly important processes
in which the analysed genes were involved while
disregarding processes that would have been found
by chance in any similarly sized gene set, was
obtained by means of overrepresentation analysis
(ORA) of the biological processes to which the
genes were annotated in the GO knowledgebase.
This identified d = 258 biological processes (GO
terms), given the p-value threshold of 1 9 106 and
the a-correction according to Bonferroni. One gene
was neglected in this analysis, COL6A4P1, the colla-
gen type VI alpha 4 pseudogene 1, because it was
not referenced in the GO.
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Subsequently, the 109 9 258 sized ‘gene to bio-
logical process matrix’ (Fig. 2) thus obtained was
analysed for functional subgroups of genes. Using
unsupervised machine-learning implemented as
self-organizing artificial neuronal network of the
Kohonen type enhanced by the U-matrix (i.e. an
emergent self-organizing map, ESOM; Ultsch and
Sieman, 1990; L€otsch and Ultsch, 2014), the high-
dimensional data space was projected onto a two-
dimensional toroid grid. On this grid, the U-matrix
was visualized by applying a geographical landscape
analogy (Fig. 3) providing a visual structure that
could be employed for clustering of genes. The
results indicated a large cluster comprising more
than half of the genes (n = 58). However, this cluster
was still composed of functionally very different
genes, pointing towards a large heterogeneity of the
genes chosen as candidate modulators of persisting
pain in the different clinical studies, or was found
with genomewide association studies (GWAS) with-
out a focus on a particular gene. In addition, six
smaller clusters were suggested, but their distinct
separation was occasionally incomplete or, according
to the U-matrix landscape analogy, they were not
clearly presented as ‘valleys’ but consisted merely of
‘mountain’ zones separated by slightly higher ridges
(Fig. 3). In ESOM/U-matrix based clustering, this
indicates rather large intracluster distances.
As the present method has been shown to be
well able to identify existent cluster structures
while being unlikely to show false clusters
(Ultsch, 2005; Ultsch and L€otsch, 2017), the main
result of this analysis was that there is consider-
able heterogeneity among the genes reported to
be involved in persisting pain without a clear
functional focus on common general processes
underlying this trait.
3.2 Functional genomics analysis of most
informative genes reported to modulate
persisting pain
In a second analytical approach, the hypothesis was
pursued that the functional genomics of persisting
pain will prevail across clinical settings irrespective
of the disease that had originally triggered the pro-
cess. However, the set intersection of the genes asso-
ciated with any of the eight different clinical settings
was empty. Nevertheless, the hypothesis that modu-
latory effects on chronic central sensitization to pain,
rather than on the underlying disease-causing pain,
are exerted by the same genes across several clinical
settings could be pursued in several genes have been
shown to be involved in more than one clinical set-
ting of chronic central sensitization.
To identify how many clinical settings qualify as a
cut-off, an ABC analysis was applied to the sum of
settings in which each of the 110 genes was involved
(column sums in the matrix plot in Fig. 4, top). This
assigned 22 genes to ABC sets ‘A’ or ‘B’ (Table 2)
that were included in further analysis as they could
be regarded as best suited to perform an evidence-
based functional genomics analysis of chronic central
sensitization to pain, considering the difficulty of
separation between a modulation of the pain-causing
disease from a modulation of the perception and
processing of chronic nociceptive input when a gene
was involved only in a single clinical setting of per-
sisting pain.
ORA identified 64 GO terms associated with this
particular subset of genes more often than expected
by chance, given the chosen p-value thresholds of
1 9 106 and correction for multiple testing accord-
ing to Bonferroni. These terms provided a functional
genomics perspective of the genes with variants
Figure 3 Result of a projection of the genes carrying variants reportedly modulating persistent pain onto a self-organizing map (SOM) of the Kohonen
type (Kohonen, 1982). Following projection of the genes on the grid of neurons, based on their functional annotations in the Gene Ontology knowledge-
base (Ashburner et al., 2000) (n = 109; one of the 110 genes in Table 1 was not annotated in the GO), the distance and density structures in the high-
dimensional space were visualized using the so-called U*-matrix (Ultsch, 2003). Specifically, a trained SOM represents a topology preserving mapping of
n high-dimensional data points xi ε D, where D denotes the data space, onto a two-dimensional grid of neurons. A neuron n and the neurons in its neigh-
bourhood N(n) on the output grid of the SOM represent points in the data space. The sum of distances between n and N(n) in the high-dimensional space,
combined with the respective density probabilities, is shown on a U*-matrix as a height value (U-height) at neuron n. Large U-heights mean that there is a
large gap in the data space. Low U-heights mean that the points are close to each other within the data space (L€otsch and Ultsch, 2014). The dots indicate
the so-called best matching units (BMUs) of the SOM, which are those neurons whose weight vector is most similar to the input, i.e. the representation of
the vector of the annotation of genes to GO terms. The BMUs are coloured according to the obtained clustering of the data space and labelled with the
respective gene symbols. The cluster structure emerged from visualization of distances and density structures between neurons in the high-dimensional
space by means of a U*-Matrix (Izenmann, 2009). Top: here, the genes represented by the BMUs are annotated. Bottom: 3D-display of the U-matrix in
which the ‘valleys’, ‘ridges’ and ‘basins’ can be seen. Valleys indicate clusters of functionally similar genes based on the significant GO term annotations.
The figure was created using the R software package (version 3.3.2 for Linux; http://CRAN.R-project.org/; R Development Core Team, 2008) using our R
library ‘Umatrix’ (https://cran.r-project.org/package=Umatrix; L€otsch et al., 2018a).
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shown to modulate the persisting pain sensitization
phenotype in different clinical settings. Their graphi-
cal representation visualized their arrangement in
the GO polyhierarchy (Fig. 5). Following application
of functional abstraction (Ultsch and L€otsch, 2014),
the main biological functions of the 22 gene carrying
variants modulating persisting pain, were grouped
around seven centres of biological activity or func-
tional areas (Table 2; Fig. 5).
A first functional area to emerge was ‘immune sys-
tem process’, represented in this particular gene set as
an important common biological function (Fig. 5 mid-
dle left). The most significantly associated immune
regulatory processes were ‘regulation of immune
effector processes’ (GO:0002697, p = 2.8 9 108) and
‘positive regulation of lymphocyte mediated immu-
nity’ (GO:0002708, p = 2.9 9 107). A second func-
tional area centred on ‘reactive oxygen species
metabolic process’ (GO:0072593, p = 4.5 9 1011)
and comprised mainly nitric oxide signalling related
processes (Fig. 5 middle right) such as ‘nitric oxide
biosynthetic process’ (GO:0006809, p = 3.2 9 1012)
and its regulation.
Further functional areas, however, mainly
reflected processes known from previous research to
contribute to pain (L€otsch et al., 2013; Ultsch et al.,
2016). This included ‘response to stimulus’ with sev-
eral subordinate terms, such as ‘response to stress’
(GO:0006950, p = 5.2 9 107), comprising the reac-
tion of the body to several challenges such as ‘re-
sponse to chemical’ (GO0042221, p = 1.1 9 1010)
and ‘defense response’ (GO:0006952, p = 1.8 9
107). Further subordinate areas included ‘inflam-
matory response’ (GO:0006954, p = 2.8 9 108) and
‘response to other organism’ (GO:0051707,
p = 2.5 9 1010) to which ‘response to bacterium’
(Fig. 5 middle left) was related. These response areas
were also associated with the more general func-
tional area ‘regulation of multicellular organismal
process’ (GO: 51239, p = 1.2 9 107). In addition,
the associated functional area ‘transport’, mainly
comprised subordinate processes related to ion or
transmitter transport such as ‘regulation of ion
transport’ (GO:0043269, p = 9 9 109) or ‘regula-
tion of secretion by cell’ (GO:1903530, p = 4.1 9
107). Finally, a functional area ‘neurological system
process’ (GO:0050877, p = 2.4 9 107), as a more
specific subordinate term to ‘system process’,
reflected the expected involvement of nervous sys-
tem related processes with pain.
The main results, i.e. the most specific functional
areas pointing at immune processes and nitric oxide
Figure 4 Number of clinical settings in which variants in the respective genes have been reported to be associated with modified phenotypes of
chronic pain. Left: Matrix plot of the clinical settings (rows) versus the genes (n = 110, columns split in two halves, sorted for column sums in
descending order). The column sums are displayed in the bottom row below the matrix. The numbers are displayed colour-coded with 0 = white,
1 = blue, >1 darker blue). Right: ABC plot of the cumulative distribution function of the sums of clinical settings in which the genes were report-
edly involved (column sums in the top matrix; bottom line). The ABC set limits are indicated as red lines (for further details about an ABC analysis,
see (Ultsch and L€otsch, 2015)). The figure was created using the R software package (version 3.3.2 for Linux; http://CRAN.R-project.org/; R Develop-
ment Core Team, 2008). Specifically, the matrix plot was created using the ‘heatmap.2’ functions of the R package ‘gplots’ (Warnes G. R.; https://
cran.r-project.org/package=gplots), with the build-in clustering of the plotting routine disabled (R switches ‘Colv=FALSE, Rowv=FALSE’). The ABC
curve was drawn using our R library ‘ABCanalysis’ (https://cran.r-project.org/package=ABCanalysis; Ultsch and L€otsch, 2015).
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signalling as key biological processes involved in
persisting pain across more than a single clinical set-
ting, prevailed when narrowing the gene set further
on those that are also listed in the PainGenes data-
base (Fig. 6). As the set intersection between the 22
genes identified above and the genes of the Pain-
Genes database included only n = 13 genes, the
ORA applying the same statistical thresholds
resulted in fewer additional significant GO terms
(Fig. 6).
Table 2 Genes for which functional involvement of their variants has been reported in more than one clinical setting of persisting pain (number
of these clinical settings given in the third column) were assigned to ABC sets ‘A’ or ‘B’ (Figure 4), comprising the most profitable information for






























5 X O O X X X X
IL-6 Interleukin-6 4 X X X X X X X
SCN9A Sodium channel, voltage-
gated, type IX alpha
subunit
4 X O O X X O O
TNF Tumour necrosis factor 4 X X X X X X X
ADRB2 Adrenoceptor beta 2,
surface
3 X O O X O X O
ESR1 Oestrogen receptor 1 3 X O X O O X X
IL-10 Interleukin-10 3 X X X X X X X
IL-1RN Interleukin-1 receptor
antagonist
3 X X O X X X X
TGFB1 Transforming growth
factor, beta 1
3 X X X X O X X
CRHBP Corticotropin-releasing
hormone binding protein
2 X O O X X X X
DRD4 Dopamine receptor D4 2 X O O X X X X
GCH1 GTP cyclohydrolase 1 2 X X X O X O X
GSTM1 Glutathione S-transferase
mu 1
2 X O O O O O O
HLA-B Major histocompatibility
complex, class I, B
2 X X O O O X X
IL-1B Interleukin-1, beta 2 X X X X O X X
IL-4 Interleukin-4 2 X X X X O X X
IL-4R Interleukin-4 receptor 2 X X O X O X X
P2RX7 Purinergic receptor P2X,
ligand gated ion channel,
7
2 X X X X X X X
SCN5A Sodium channel, voltage-
gated, type V alpha
subunit
2 X O O X X X O
SOD2 Superoxide dismutase 2,
mitochondrial
2 X X X O X O X
TPH2 Tryptophan hydroxylase 2 2 X O O O O O O
TRPV1 Transient receptor
potential cation channel,
subfamily V, member 1
2 X O O X X O O
Sum 22 12 10 16 13 16 16
The right part of the table displays the functional areas (Figure 5) or groups of biological functions in which the gene set is involved, together with
their association with each gene (X = yes, O = No). The precise definition of the GO terms can be obtained using AmiGO search tool for GO at
http://amigo.geneontology.org/ (Carbon et al., 2009).
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4. Discussion
The present analysis used empirical evidence for
functional human genetic variants to approach the
genetic architecture of persisting pain. Although the
evidence was collected from separate studies, its com-
bination permitted a limited genomewide association
analysis of the trait. Methods for data mining and
machine-learned knowledge discovery were applied
to publicly available databases in order to relate
knowledge, acquired in the context of clinical pain
research, on genes that modulate the phenotype of
persisting pain with data on the biological functions
of these human genes acquired in any context, with-
out restriction to pain research (L€otsch et al., 2013).
The initial analysis of the whole set of genes
showing positive results from clinical pain associa-
tion studies indicated that, apart from a minority of
genes that could be topically grouped such as inter-
leukin or histocompatibility complex-related genes,
most genes displayed very heterogeneous functions
and the analysis did not illuminate the pathophysiol-
ogy of persisting pain beyond the functions of the
single genes. This was probably due to the fact that
data were drawn mainly from candidate gene or
GWAS approaches. This selection probably intro-
duced a research bias by (1) addressing genetic mod-
ulators in the context of the underlying disease and
(2) including a selection of genetic markers that
mimic other successful reports of comparable studies.
The situation became clearer when the analytical
focus was narrowed to genetic modulations consis-
tently observed across several clinical conditions with
potential underlying painful diseases. This reduced
the analytical bias generated by genetic modulations
responsible for a specific pain-causing disease and is
in keeping with the contemporary approach to per-
sisting pain as a distinct condition of central sensitiza-
tion to pain and not merely a symptom of another
underlying chronic disease. Consequently, it would
be expected that the trait is modulated by specific
genes which should be reflected by observations on
its modulation in clinical research. The mathemati-
cally precise calculation provided by the ABC analysis
(Ultsch and L€otsch, 2015), developed in order to select
the most promising or profitable items from a larger
set of items, resulted in identification of a set of 22
genes which could be then be assessed in a computa-
tional functional genomics analysis of persisting pain.
A major finding of this analysis of available evi-
dence on genetic modulation of persisting pain was
the particular importance of two groups of biological
processes indicating involvement (1) of the immune
system and of (2) nitric oxide signalling in persisting
pain. Involvement of both processes is biologically
highly plausible; however, their emergence as major
process groups from a functional genomics analysis of
data from clinical genetic research on persisting pain
was not anticipated. Specific roles for the present
subset of 22 genes, with repeated evidence for
involvement in persisting pain, were exhibited by the
12 genes annotated as ‘immune system process’
(Table 1). This subset included interleukin (IL-1B, IL-
4, IL-6, IL-10) (Dinarello, 1994; Choi and Reiser,
1998; Mocellin et al., 2004; Nemeth et al., 2004),
interleukin receptor (IL-1RN, IL-4R) (Bittar and Bit-
tar, 1996) and histocompatibility complex-related
(HLA-B) genes (Dupont and Ceppellini, 1989), which
have been shown to be involved in immunological
mechanisms of pain (Sato et al., 2002; de Rooij et al.,
2009). This is also supported by published evidence
for the further genes in this list, such as, TNF (Vas-
salli, 1992; Franchimont et al., 1999), TGFB1 (Li
et al., 2006), GCH1 (Schott et al., 1993), P2RX7
(Schwartz et al., 2009) and SOD2 (Wells et al., 2003).
The second major process group emerging from the
functional genomics analysis of the key evidence for
genetic modulation of clinical persisting pain was
nitric oxide signalling, in particular metabolic pro-
cesses, summarized in this context under the GO
term ‘reactive oxygen species metabolic process’
which includes the genes IL-6 (Deakin et al., 1995),
TNF (Deakin et al., 1995; Katusic et al., 1998), ESR1
(Clapauch et al., 2014), IL-10 (Cattaruzza et al.,
2003), TGFB1 (Saura et al., 2005), GCH1 (Katusic
et al., 1998; Zhang et al., 2007), IL-1B (Katusic et al.,
1998), IL-4 (Coccia et al., 2000), P2RX7 (Gendron
et al., 2003), SOD2 (Fridovich, 1978). It is widely
accepted that nitric oxide (NO) is critically involved
in persisting pain (Chung, 2004). It has been shown
that NO is produced in the spinal dorsal horn neu-
rons in response to extensive nociceptive inputs and
then it diffuses out and increases neurotransmitter
release from primary afferent terminals, thereby con-
tributing to central sensitization and persisting pain
(Lin et al., 1999). Recent findings seem to indicate
that not only NO is a mediator of persisting pain that
accompanies inflammation, other reactive oxygen
species like superoxide (SO) might also participate in
persisting pain (Schwartz et al., 2008). Kim and col-
leagues found that NO and SO contribute to persist-
ing pain via two separate and independent pathways
and a recent study has shown that capsaicin-induced
hyperalgesia is a consequence of superoxide build-up
in spinal dorsal horn neurons. Superoxide dismutase
(SOD-2) encoded by gene SOD2 is a major
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determinant suggesting a therapeutic potential for
the manipulation of spinal SOD-2 activity in pain
conditions (Schwartz et al., 2009).
The role of cytokines was further highlighted by
further restricting the gene subset most consistently
related to persisting pain by identifying the appear-
ance of the relevant gene in an independently cre-
ated list of 535 so-called pain genes (Ultsch et al.,
2016). These were genes relevant to pain listed by
several sources: mainly the Pain Genes Database
(http://www.jbldesign.com/jmogil/enter.html (Lacroix-
Fralish et al., 2007). The overlap of the set of the 22
genes, with repeated records of variants that modu-
late the clinical phenotype of persisting pain, with
the 535 ‘pain genes’ comprised 13 genes (ADRB2,
COMT, ESR1, GCH1, IL-10, IL-1B, IL-4, IL-6, P2RX7,
SCN9A, SOD2, TNF, TRPV1). After performing a simi-
lar ORA (Fig. 6) as that described above, these 13
genes were found to be mainly involved in cytokine
production, covered by the significant GO terms
‘chemokine metabolic process’ (GO:0050755,
p = 3.3 9 107), ‘nitrogen compound metabolic pro-
cess’ and again ‘response to stimulus’, the most sig-
nificant term being ‘nitric oxide biosynthetic process’
(GO:0006809, p = 1 9 1014).
The involvement of the immune system in persist-
ing pain is plausible from a biological perspective.
One of the sites of interaction of the immune system
with persisting pain has been identified as neuroim-
mune crosstalk at the glial–opioid interface (Tian
et al., 2012). Previous research has shown that glial
and immune cells, including astrocytes, microglia/
macrophages, as well as T lymphocytes, are key cells
activated during persisting pain, which contribute to
pain persistence (Calvo et al., 2012; von Hehn et al.,
2012). A role for local production of cytokines in the
central nervous system during inflammatory condi-
tions associated with persisting pain, such as rheuma-
toid arthritis (Lampa et al., 2012) or fibromyalgia
(Kadetoff et al., 2012), as well as evidence for central
nervous system sensitization by cytokines (Aden
et al., 2010) also suggests such an immune system
interaction with persisting pain states. Indeed, it has
recently been suggested that the predominance of
pain sensitization during chronic diseases in women
is closely linked to the effects of female sex hormones
on the neuroimmune system (Rosen et al., 2017).
The present results clearly support the modulation
of neuroimmune system processes as a promising
strategy in the development of novel analgesic drugs
against persisting pain. This may be possible along sev-
eral lines. For example, involvement of glial cells in
opiate actions has been shown recently (Chen et al.,
2010; Boue et al., 2012). Consequently, the elucida-
tion of pain- and opioid-induced mechanisms at the
level of glial and immune cells could lead to improve-
ment of pain management. In an animal model, ibudi-
last, a nonselective phosphodiesterase-inhibiting,
anti-inflammatory drug that also blocks glial activa-
tion probably via antagonism at the Toll-like receptor
4 (Jia et al., 2012), restored morphine-induced
antinociception following tolerance development (Lil-
ius et al., 2009). Similarly, minocycline, a tetracycline
that inhibits microglial activation and proliferation,
also seems to attenuate morphine tolerance in mouse
models of neuropathic pain (Chen et al., 2010).
Hence, increasing evidence points towards the
immune system as a potential source of future targets
for analgesic drugs directed against persisting pain.
By gathering the relevant reports, the present anal-
ysis centres on the current evidence about a genetic
modulation of persisting pain on a gene level, with-
out going into the details of single nucleotide poly-
morphism level as usually applied in review papers.
However, the approach was centred on machine-
learned knowledge discovery from the gathered evi-
dence and was based on published evidence gathered
from studies in which the authors had used a candi-
date gene approach or had performed a GWAS with-
out a gene-specific hypothesis. Therefore, the present
analysis implies a research bias given by the original
hypotheses or on the inclusion of frequently
addressed genetic variants in the analysed studies.
The question addressed with the present analysis was
about the greater functional perspective emerging
from successful clinical studies of the genetic modula-
tion of persisting pain. Importantly, while the analy-
sis is biased with respect to the gene selection, made
by the authors of the included studies, its results are
not biased for a particular functional genomics per-
spective as this had not been an gene inclusion crite-
rion in the analysed studies. Nevertheless, the
present selection of repeatedly reported associations
implies an advantage of frequently included genes
that have been attracted research interest through
the last several years, such as OPRM1, GCH1 or COMT.
With the caution advised by the implicit research
bias regarding the gene selection, the results of the
present analysis were (1) unexpected considering
that hypotheses about the involvement of immune
system processes or of nitric oxide signalling were
not preformulated for the present analysis and (2)
biologically plausible and completely compatible
with current research activities on persisting pain in
the light of increasingly acknowledgement of an
involvement of immune processes that has attracted
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concerted research activities (Kringel and L€otsch,
2015), including that on the role of the glial–opioid
interface in persisting pain (http://gloria.helsinki.fi).
Hence, although the evidence was generated in sepa-
rate studies, the combination of positive findings of a
genetic modulation of persisting pain allows a lim-
ited yet valid genomewide analysis of the trait, pro-
viding a more comprehensive picture of functional
background of persisting pain from genomics per-
spective than associations of single genotypes.
5. Conclusions
While many studies have focused on particular
genes, the present analysis pursued the question
whether their combined results may provide more
complex insights into the pathophysiology of persist-
ing pain in humans. In keeping with the contempo-
rary trend towards ‘big data’ analysis in biomedical
research, the current empirical data on modulation
of persisting pain via human genetic polymorphisms
have been subjected here to a computational func-
tional genomics analysis. This evidence was then
analysed for emergent, principal pathophysiological
processes that characterize persisting sensitization to
pain. Analysis of 110 unique genes, with variants
that have been reported to modulate the clinical
phenotype of persisting pain, led to the selection of
functionally heterogeneous genes. By focusing on
genes that have been repeatedly associated with
modulation of persisting pain phenotypes in several
clinical settings, a clearer picture emerged of the
main processes identified by current human genetics
research on persisting pain. A mathematically sup-
ported, precise selection of a subset of genes was
possible using a computational functional genomics
approach. On this basis, including the research bias
of current clinical genetic association studies, the
evidence gathered so far points to the view of per-
sisting pain as a trait resulting from alterations in the
immune system and/or in nitric oxide signalling, a
concept that is biologically highly plausible and
agrees with other lines of pain research. While ana-
lysing existing evidence and therefore limited to pre-
viously shown functional pathways, the present
computational functional genomics-based approach
provides a computational systems-biology perspective
on chronic sensitization to pain by summarizing the
empirical evidence gathered in many separate stud-
ies. Moreover, human genetic research on persisting
pain emphasizes the immune system as a potential
source of important future targets for analgesic drugs
directed against persisting pain and demonstrates
that contemporary machine-learned methods offer
innovative approaches to knowledge discovery from
previous evidence.
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